Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome…

StudyDrug design, development and therapy· 2026

Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.

Haoqiong Sun, Ling Guo, Panpan Shao … Liru Qiu

Pediatric NephrologyStudyQ1IF 6.0

No relapses in children given obinutuzumab after rituximab failure for nephrotic syndrome

Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.

Haoqiong Sun … Liru Qiu

Drug design, development and therapy · 2026

Purpose

This preliminary study aimed to describe the effectiveness and safety of obinutuzumab as a rescue and maintenance anti-CD20 strategy in children with difficult-to-treat nephrotic syndrome after failure or intolerance of rituximab-based multi-target immunosuppression.

Methods

This exploratory single-center retrospective real-world study included consecutive children who received obinutuzumab between April 2024 and January 2025.

Results

no relapses after obinutuzumab in children who had failed rituximab

2.5episod

Before obinutuzumab

0episod

After obinutuzumab

More results

All eight efficacy-set patients achieved complete peripheral B-cell depletion and remained depleted at 6 months.

In the safety set, one child developed severe anaphylactic shock during the first infusion; infectious events were limited to CTCAE grade 1-2 events.

“

Conclusion · 1 of 2

In this exploratory, hypothesis-generating study, obinutuzumab was associated with a favorable relapse profile, sustained peripheral B-cell depletion, and reduction of background immunosuppression in a highly selected pediatric population.

Conclusion · 2 of 2

Larger prospective studies are required to confirm these preliminary observations and define long-term safety.

Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.

Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study.

Related papers